To recover your password please fill in your email address
Please fill in below form to create an account with us
MOST 15 SUBSTUDIES 33-34: DURVALUMAB PLUS ACALABRUTINIB
A single arm, open label, signal seeking, phase II trial of the activity of Durvalumab in combination with Acalabrutinib in patients with high-grade B cell lymphoma.
The aim of this substudy is to assess the clinical activity of durvalumab and acalabrutinib in patients with high grade B cell lymphoma.
Adult patients with pathologically confirmed high grade B cell lymphoma enrolled in the MoST program for molecular screening are eligible for this study.
Professor Steven Lane